Why did Alkermes (ALKS) stock move recently?

On 7/29/2026, Alkermes moved -4.3% — Alkermes shares fell after Q2 results showed an EPS and revenue beat, but the reaffirmed full-year 2026 revenue guidance midpoint came in below Street consensus, triggering profit-taking on a stock that had already risen sharply YTD. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is Alkermes (ALKS) overvalued or fairly valued?

MarketChacha shows Alkermes's valuation in context — a trailing P/E of about 76.9, a forward P/E of about 26.1, a price-to-book of about 4.4 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Alkermes's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (1.41×) from reported figures — education, not a rating.

What is Alkermes's revenue?

Alkermes reported revenue of $1.5B for FY2025, with net profit of $241.7M, per official filings.

What is the share price of Alkermes (ALKS)?

Alkermes last traded at $46.88 (-1.8% on the day), as of 9/3/2026 — a delayed quote shown for education, not investment advice.

Alkermes

ALKS · NYSE · Healthcare · United States

Snapshot

TickerALKS

ExchangeNYSE

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

CountryUnited States

Employees2,050

HeadquartersDublin, Ireland

Websitewww.alkermes.com

Filings tracked25

About Alkermes

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Who owns it

Insiders1.4%
Institutions98.6%
Public & other0.0%

579 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.17.43%
Baker Bros. Advisors, LP5.97%
Vanguard Portfolio Management LLC5.66%
State Street Corporation5.46%
Vanguard Capital Management LLC4.48%
Price (T.Rowe) Associates Inc4.02%
Renaissance Technologies, LLC3.85%
Geode Capital Management, LLC2.67%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

Margin has compressed by about 5.0 points over the period — profitability is trending down.

Cash conversion1.41×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend21.4% → 16.4%

Margin has compressed by about 5.0 points over the period — profitability is trending down.

Growth qualityrev -6% · PAT -18%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $473.4M · EPS 0.09

Est. earnings growth -81.6%

Next fiscal year

Rev $1.9B · EPS 1.83

Est. earnings growth +43.4%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$1.5B

Net margin

16.4%

ROE

13.3%

Revenue CAGR (2y)

-5.8%

Profit CAGR (2y)

-17.6%

EPS (FY2025)

1.43

Net profit (FY2025)

$241.7M

Ask MarketChacha about ALKS

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Jul 29, 2026
Alkermes shares fell after Q2 results showed an EPS and revenue beat, but the reaffirmed full-year 2026 revenue guidance midpoint came in below Street consensus, triggering profit-taking on a stock that had already risen sharply YTD.
source 1 ↗source 2 ↗· confidence: high
Jul 28, 2026
Alkermes stock fell after reporting Q2 results that beat revenue and EPS estimates, as the company updated full-year GAAP net loss guidance to $95-115M (from prior expectations) due to higher contingent consideration costs tied to the Avadel acquisition, while reaffirming revenue guidance.
source 1 ↗source 2 ↗source 3 ↗· confidence: high

Daily moves with the verified reason behind them. Education only — not investment advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$1.5B	$241.7M	1.43	16.4%	13.3%
FY2024	$1.6B	$367.1M	2.17	23.6%	25.1%
FY2023	$1.7B	$355.8M	2.10	21.4%	29.6%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$496.0M	$501,000	0.00	0.1%
2026Q1	$392.9M	$-66.5M	-0.40	-16.9%
2025Q3	$394.2M	$82.8M	0.49	21.0%
2025Q2	$390.7M	$87.1M	0.52	22.3%
2025Q1	$306.5M	$22.5M	0.13	7.3%
2024Q3	$378.1M	$92.4M	0.55	24.4%
2024Q2	$399.1M	$91.4M	0.53	22.9%
2024Q1	$350.4M	$36.8M	0.21	10.5%
2023Q3	$380.9M	$47.8M	0.28	12.5%
2023Q2	$617.4M	$237.1M	1.38	38.4%
2023Q1	$287.6M	$-41.8M	-0.25	-14.5%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K/A — Executive/director change
SEC8/3/2026
10-Q filing
SEC7/28/2026
8-K — Results of operations, Exhibits
SEC7/28/2026material
8-K — Termination of agreement
SEC7/8/2026material
8-K — Reg FD disclosure, Other events, Exhibits
SEC6/15/2026material
8-K — Executive/director change, Shareholder vote results, Exhibits
SEC5/20/2026material
8-K — Reg FD disclosure, Other events, Exhibits
SEC5/12/2026material
8-K — Results of operations, Exhibits
SEC5/5/2026material
10-Q filing
SEC5/5/2026
8-K/A — Exhibits
SEC5/1/2026
8-K — Results of operations, Exhibits
SEC2/25/2026material
10-K filing
SEC2/25/2026
8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC2/25/2026material
8-K — Material agreement, Termination of agreement, Completion of acquisition/disposition, Material financial obligation, Reg FD disclosure, Exhibits
SEC2/12/2026material
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC1/12/2026material
8-K — Reg FD disclosure, Other events, Exhibits
SEC1/6/2026material

2025

8-K — Material agreement, Material financial obligation, Reg FD disclosure, Exhibits
SEC11/19/2025material
8-K — Reg FD disclosure, Other events, Exhibits
SEC11/12/2025material
8-K — Results of operations, Exhibits
SEC10/28/2025material
10-Q filing
SEC10/28/2025
8-K — Material agreement, Results of operations, Material financial obligation, Reg FD disclosure, Exhibits
SEC10/22/2025material
8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC9/12/2025material
8-K — Material agreement, Other events
SEC9/12/2025material
8-K — Reg FD disclosure, Exhibits
SEC9/8/2025material
8-K — Results of operations, Exhibits
SEC7/29/2025material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.